Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 67

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 67
---
 1,399 |
| Financial income, net               |     |            |   (69 | ) |     |             |     2 |
| Net loss and comprehensive loss     |     |            | 1,606 |   |     |             | 1,401 |

| *) | less than 1 thousand |

Research and Development Expenses

Successor’s research and development
expenses totaled $609 thousand for the six months period ended June 30, 2025, representing a decrease of $537 thousand, or 46.8%, compared
to Predecessor’s $1,146 thousand for the same period. The research and development expenses comprise mainly from salaries and related
expenses, from share based payment expenses and other expenses. The decrease was mainly due to lower share based payment expense recorded
in the six months period ended June 30, 2025 compared with the same period in 2024.

<div align='center'>38</div>

General and Administrative Expenses

Successor’s general and administrative
expenses totaled $1,066 thousand for the six months period ended June 30, 2025, representing an increase of $813 thousand, or 321.3%,
compared to Predecessor’s $253 thousand for the same period. The general and administrative expenses comprise mainly from salaries
and related expenses, share based payment expenses, professional services and other expenses. The increase was primarily attributable
to higher share-based payment expense, Successor’s salaries and related expenses and Successor’s professional services for
such period compared to not significant or no such expenses in the Predecessor for the same period.

Operating Loss

As a result of the foregoing, Successor’s
operating loss totaled $1,675 thousand for the six months period ended June 30, 2025, representing an increase of $276 thousand, or 19.7%,
compared to Predecessor’s $1,399 thousand loss for the same period.

Financing income, Net

Successor recognized financing income, net
of $69 thousand for the six months period ended June 30, 2025, representing an increase of $71 thousand, or 3550.0%, compared to Predecessor’s
finance expense, net of $2 thousand for the same period. The increase in finance income, net was primarily attributable to Successor’s
interest income from short term deposits and higher exchange rate differences between the U.S. dollar and the New Israeli Shekel.

Net and Comprehensive